RA
PLRX icon

Rise Advisors’s Pliant Therapeutics PLRX Stock Holding History

Rise Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-740
Closed -$1.09K – 1081
2025
Q3 		$1.09K Hold
740
– – ﹤0.01% 1268
2025
Q2 		$858 Buy
+740
New +$1.05K ﹤0.01% 1309

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Rise Advisors's PLRX Position: Q4 2025 in Review

Rise Advisors sold out of Pliant Therapeutics (PLRX) in Q4 2025, closing a stake of 740 shares — an estimated $1.09K sold.

Rise Advisors first reported a position in PLRX in Q2 2025 and held it in 2 quarters. The position peaked at $1.09K in Q3 2025. 97 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • Rise Advisors reported no remaining Pliant Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 740 Pliant Therapeutics shares in Q4 2025, an estimated $1.09K.
  • Rise Advisors first reported a position in Pliant Therapeutics in Q2 2025 and held it in 2 quarters.
  • Rise Advisors's Pliant Therapeutics position peaked at $1.09K in Q3 2025.
  • 97 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.